Contents


About the Foundation


Stephen L. DeFelice, MD


DeFelice Commentaries


NREA, Nutraceutical Research and Education Act


Television Debates
and Videos


Library


Conferences


Links


Contact Us


Board of Directors


Senator Harkin on FIM




Google

Home


The Patient Always
Gets Screwed


Promising Ovarian Cancer Therapy Blocked

Carnitine-Ovarian Cancer Promise and a Failed Attempt at a Clinical Study


When Was The Last Cure?


Translational Science - How Doctornauts Can Help


Senator Tom Harkin (D-IA) has been one of the leaders in Congress on Translational Science.


Doctornauts Barry Marshall and Lukas Wartman: Living Proof of the Urgent Need for the Doctornaut Act



View the Discussion Draft of the Doctornaut Act Prepared by Former Senator Bill Frist.




Defelice Commentary of July 2004

Stephen L. DeFelice, M.D.

The vast majority of Americans are correct in their belief that modern technology offers enormous medical promise. They are unaware, however, that the barriers to deliver this medical promise are also enormous. For decades we have been told about exciting potential medical breakthroughs, but such news is invariably followed by the message that it will take a significant amount of time before these potential breakthroughs become available to doctors to patients. But, unbelievable as it may seem, not once have I heard the question asked, "Why are they taking so long to arrive?"

My answer to the question is that the American system is misanthropic in that, like a stealth bomber, is effectively designed to block the clinical testing of these therapies without being noticed. The result? Many millions of patients have or are needlessly suffering and dying before they should.

I have had a long career in scientific-medical research and have experienced, firsthand, the formidable barriers to medical discovery. For this reason, I decided to create this column in order to both offer ways to effectively diminish these barriers as well as discuss potential new therapies themselves.

Occasionally, guest authors will contribute to this column. I do invite comments and criticism from the readers. But, unfortunately, because of the volume, I am not able to respond to all. I will, however, select a few which will follow each column.